AMPA Archives

Banerjee team at College of Staten Island

Correcting Fragile X Syndrome Deficits by Targeting Neonatal PKCε Signaling in the Brain

February 17, 2022

Enhancing PKCε in early development normalized oxytocin, AMPAR signaling, and adult behavior in Fragile X mice, highlighting PKCε as a promising therapeutic target.

Cellular-Specific Therapeutic Targeting of Inhibitory Circuits in Fragile X Syndrome

April 21, 2021

The team studied how inhibitory brain circuits malfunction in Fragile X and tested ways to restore balance by targeting mGluR and endocannabinoid signaling.

Auditory Dysfunction in Fragile X Syndrome in a Mouse Model of Fragile X

April 5, 2021

FRAXA-funded studies found Fragile X mice show altered auditory circuit function with delayed startle timing and reduced prepulse inhibition, mirroring human sound sensitivity.

Nazim Kourdougli and Carlos Portera-Cailleau

Correcting Sensory Processing in Fragile X Mice by Modulating Kv3.1

June 19, 2019

FRAXA funded UCLA research on a Kv3.1-targeting drug to ease sensory issues in Fragile X. This work built on Yale-led work now also being pursued by Autifony Therapeutics.

Developmental Profile of Glutamatergic Synapses in Fragile X

May 2, 2019

A FRAXA fellowship helped reveal how glutamate receptors at synapses develop differently in Fragile X, offering clues to improve learning and memory.

Enhancing NMDA Receptor Signaling to Treat Fragile X Syndrome

March 7, 2019

FRAXA-backed work revealed NMDA receptors may hold the key to correcting brain signaling in Fragile X, pointing to new treatment strategies.

Investigating Gene Reactivation to Treat Fragile X Syndrome

September 22, 2017

With a $180,000 grant from FRAXA Research Foundation, Dr. Jeannie Lee and her team at Harvard are working to reactivate the gene that is silenced in Fragile X syndrome.

Paul Lombroso, PhD, Yale University, FRAXA Investigator

Inhibitors of STEP as a Novel Treatment of Fragile X Syndrome

February 26, 2015

STEP inhibition reversed behavioral and synaptic Fragile X deficits in mice (Neuropharmacology, 2018), highlighting STEP as a promising treatment target.

Social Behavior as an Outcome Measure for Fragile X Clinical Trials

September 13, 2013

FRAXA funding helped identify reliable social behavior tests in Fragile X mice and showed an mGluR5 treatment could improve sociability, guiding future trials.

AMPAkines and BDNF in Fragile X: UCI Researchers Restore Memory Process in Fragile X

February 14, 2008

FRAXA’s $104K grant supported Dr. Julie Lauterborn at UC in studying dendritic spines and memory-related treatment targets in Fragile X mice.

Improving Memory Reversal Testing and Treatment with AMPAkines in the Fragile X Knock-Out Mouse

June 27, 1998

FRAXA-funded Dr. W. Ted Brown studied learning deficits in Fragile X mice and tested Ampakine drugs for potential treatment.

Correcting Fragile X Syndrome Deficits by Targeting Neonatal PKCε Signaling in the Brain

Cellular-Specific Therapeutic Targeting of Inhibitory Circuits in Fragile X Syndrome

Auditory Dysfunction in Fragile X Syndrome in a Mouse Model of Fragile X

Correcting Sensory Processing in Fragile X Mice by Modulating Kv3.1

Developmental Profile of Glutamatergic Synapses in Fragile X

Enhancing NMDA Receptor Signaling to Treat Fragile X Syndrome

Investigating Gene Reactivation to Treat Fragile X Syndrome

Inhibitors of STEP as a Novel Treatment of Fragile X Syndrome

Social Behavior as an Outcome Measure for Fragile X Clinical Trials

AMPAkines and BDNF in Fragile X: UCI Researchers Restore Memory Process in Fragile X

Improving Memory Reversal Testing and Treatment with AMPAkines in the Fragile X Knock-Out Mouse

Support FRAXA

Get In Touch!

Explore Fragile X & Research

Get FRAXA Updates